Tesamorelin

Product description

Tesamorelin is a synthetic version of human GHRH – growth hormone-releasing hormone, the peptide your hypothalamus uses to tell the pituitary gland to release growth hormone. You'll also see it called TH9507 in older papers, or more generally described as a GHRH analogue or GRF analogue. Same molecule, different names, depending on when paper was written. For researchers looking to buy Tesamorelin peptide, understanding these alternative names can help when comparing research materials.

Structurally, Tesamorelin is very close to the natural 44-amino-acid GHRH sequence. The only change was intentional: the N-terminal tyrosine was attached to a trans-3-hexenoic acid group. That one tweak is what makes the whole thing work as a research tool – it slows down enzymatic breakdown, so the molecule sticks around longer, but doesn’t lose its ability to activate the GHRH receptor.

And that’s really what it’s all about studying it. Rather than giving growth hormone directly, TH9507 nudges the pituitary into releasing its own GH, which then drives up IGF-1 downstream. That gives researchers a way to look at the GH/IGF-1 axis from further upstream than usual, and track what happens as the signal moves through the pathway.

Most of the clinical work on Tesamorelin has centered on metabolism – visceral fat especially, but also lipid markers, liver fat, glucose handling, and more recently, some neurocognitive angles. Some of this evidence is genuinely solid. Some of it, less so. Worth being upfront about that.

Why study Tesamorelin?

The best-documented research area, by far, is visceral fat in people with HIV-associated lipodystrophy. And it wasn't just a "does it cause weight loss" question – researchers specifically wanted to know if stimulating natural GH release could target visceral fat selectively, since that fat behaves very differently, metabolically, from the fat sitting just under the skin.

One randomized trial with 412 participants gave some of the clearest early answers. After 26 weeks, the Tesamorelin group saw visceral fat drop by 15.2%. The placebo group? It went up 5.0%. Triglycerides improved too, along with the total cholesterol-to-HDL ratio. Subcutaneous fat barely moved in comparison – a good sign that this wasn't just generic, all-over fat loss.

A 12-month follow-up study told a similar story. Visceral fat dropped 10.9% in the treatment group during the first six months, versus just 0.6% on placebo. Keep going another six months, and the people who stayed on treatment pushed that reduction to roughly 18%.

Here's the interesting part, though. When participants were switched from the GHRH analogue over to placebo, a lot of that visceral fat came right back. So the effect doesn't look permanent – it seems to depend on the pathway staying switched on.

All of this eventually led to EGRIFTA, an FDA-approved tesamorelin product for reducing abdominal fat in adults with HIV and lipodystrophy. But that approval is narrow. Don't read it as a green light for general weight loss, and definitely don't assume it says anything about research-grade material specifically.

Research applications

GH/IGF-1 axis

Because it acts as a GHRH receptor agonist, Tesamorelin gets used to study how hypothalamic-pituitary signaling connects to endogenous GH release and, from there, circulating IGF-1.

That's a genuinely different setup than just injecting recombinant GH. Stimulating the natural pathway and watching the downstream response tells you something that bypassing the pituitary entirely can't. CJC-1295 + Ipamorelin comes at the same system a little differently. CJC-1295 without DAC works on the GHRH side, while Ipamorelin acts through the ghrelin receptor pathway. A CJC-1295 Ipamorelin purchase therefore gives researchers a different way to look at GH signalling than Tesamorelin alone.

Visceral fat and lipid metabolism

This is where TH9507 has the strongest research footing. Controlled trials in humans keep finding measurable drops in visceral abdominal fat, while subcutaneous fat barely reacts by comparison.

AOD-9604 has a very different background in fat-metabolism research. It's a modified fragment of human growth hormone rather than a GHRH analogue, and most of its evidence comes from preclinical work. Labs looking to buy Fragment 176-191 (AOD-9604) are therefore working with a different experimental approach to lipid metabolism.

Researchers studying Tesamorelin have also tracked triglycerides, cholesterol, glucose, and other metabolic markers alongside the body-composition changes – and the results aren't a clean win across the board. In one study, for instance, fasting glucose actually went up temporarily after two weeks, though by six months the difference from placebo had faded.

The FDA's prescribing information for the approved pharmaceutical formulation flags glucose intolerance and diabetes as areas needing clinical attention, too. So calling this peptide just a "fat reducer" leaves out a fair chunk of what's actually being studied.

Retatrutide sits in another corner of metabolic research. Instead of working through the GHRH/GH axis, it targets GLP-1, GIP and glucagon receptors. Researchers comparing RETA peptide buy options are therefore looking at a very different metabolic pathway from Tesamorelin.

Liver fat and metabolic liver research

Once researchers connected visceral fat to ectopic fat storage more broadly, the obvious next question came up: could GHRH pathway stimulation touch liver fat as well?

A six-month randomized study in 50 people with HIV on antiretroviral therapy found reductions in both visceral fat and liver fat. That led to a bigger, randomized double-blind trial in people with HIV and non-alcoholic fatty liver disease.

After 12 months, the Tesamorelin group showed a 4.1-percentage-point greater drop in hepatic fat fraction than placebo – about a 37% relative reduction from baseline. Meaningful data, no doubt. But it didn't settle the bigger question of long-term liver outcomes.

Metabolic research goes well beyond the GH axis. MOTS-c, a mitochondrial-derived peptide, has been studied in connection with cellular energy metabolism, AMPK signalling and metabolic adaptation. Labs can order MOTS-c peptide separately for research centred on those processes.

Available forms

Research-grade Tesamorelin shows up in a handful of formats, depending on the supplier and what your protocol actually needs. Researchers may order online depending on the available research format:

• Lyophilised powder in a vial – the standard lab format. Stays dry and stable until you're ready to prepare it.

• Pre-mixed liquid solution – ready to go, for protocols that call for liquid material from the start.

• Pre-mixed syringe pen / peptide pen – the prepared material paired with a pen-style delivery device. For repeated procedures, this cuts down on manual prep and makes hitting the same volume every time a lot easier.

• Nasal-spray research format – some suppliers carry this, though it's worth treating as its own distinct delivery route rather than a stand-in for the subcutaneous formulations used in the clinical trials above.

That last point matters more than it might seem. Route of administration changes pharmacokinetics and bioavailability. Nearly all the human data discussed here came from subcutaneous pharmaceutical formulations – it shouldn't just get extrapolated over to nasal or other research formats without caution.

Purita Peptides carries Tesamorelin in research pen configurations, in 10 mg and 40 mg sizes. Researchers interested in purchase Tesamorelin peptide options can compare the available configurations and sizes.

Research use only

Tesamorelin's an odd one, in a way – there's a genuinely large clinical literature behind it, and an FDA-approved drug built on the same active peptide. That gives researchers a lot more human data to work with than most experimental peptides have. But none of that makes research-grade material the same thing as an approved medicine. It isn't.

Products supplied by Purita Peptides are intended strictly for laboratory and research purposes – not for human or veterinary consumption, self-administration, diagnosis, treatment, or disease prevention.

And one more thing worth keeping in mind: results from published studies are tied to the specific population, formulation, route of administration, and conditions they were tested under. A finding from an approved pharmaceutical product doesn't automatically transfer to a research product just because the peptide sequence shares the same name.

Scientific sources

1. Falutz J, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. NEJM, 2007.

2. Falutz J, et al. Long-term Safety and Effects of Tesamorelin in HIV Patients with Abdominal Fat Accumulation.AIDS, 2008.

3. Falutz J, et al. Effects of Tesamorelin in HIV-Infected Patients with Abdominal Fat Accumulation. JAIDS, 2010.

4. Stanley TL, et al. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients. JAMA, 2014.

5. Stanley TL, et al. Effects of Tesamorelin on Non-Alcoholic Fatty Liver Disease in HIV. The Lancet HIV, 2019.

6. Ellis RJ, et al. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.The Journal of Infectious Diseases, 2025.

7. FDA. EGRIFTA SV (tesamorelin) Prescribing Information.